Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04295681
Other study ID # MMH-MAP-002
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date December 12, 2019
Est. completion date February 7, 2023

Study information

Verified date January 2023
Source Materia Medica Holding
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The clinical trial to valuate efficacy and safety of MMH-MAP in the treatment of cognitive disorders in patients with ischemic stroke in the carotid arteries.


Description:

Design: double-blind, randomized, parallel group placebo-controlled clinical study of efficacy and safety of MMH-MAP in the treatment of cognitive disorders in patients with ischemic stroke in the carotid arteries. The study will enroll hospitalized subjects of either gender aged 40-75 years old with verified diagnosis of ischemic stroke in the carotid arteries within 72 hours post debut having moderate cognitive disorders, moderate neurological deficit. At Visit 1 (day 1) the subject's complaints and medical history will be collected, objective examination, safety laboratory tests (hematology, serum chemistry, urinalysis) will be performed. The investigator will evaluate the patient's level of consciousness using The Glasgow Coma Scale, intensity of cognitive disorders using The Montreal Cognitive Assessment (МоСА), condition using National Institute of Health Stroke Scale (NIHSS) and The Modified Rankin Scale (mRs). Concomitant therapy will be recorded and changes in cerebral CT/MRI will be evaluated. If the subject meets inclusion criteria and has no exclusion criteria, he/she will be randomized to MMH-MAP or Placebo group. The first dose of the study product should be taken within 72 hours post stroke debut. At Visit 2 (day 12±3, end of hospitalization period - the last day of hospitalization due to the current stroke) complaints will be collected, objective examination findings will be recorded, monitoring of the prescribed and concomitant therapy will be performed, treatment safety, compliance and stroke severity according to NIHSS will be evaluated. By the end of hospital therapy the subject will be switched to outpatient therapy with continuation of IMP and medical assistance designed for the treatment of stroke and its sequelae. At Visit 3 (day 45±7 days) the investigator will make a phone call to the subject evaluating the treatment safety. At final Visit 4 (day 90±7 days) complaints will be collected, objective examination findings will be recorded, monitoring of the prescribed and concomitant therapy will be performed, treatment safety, compliance, condition according to NIHSS will be evaluated, mRs, Clinical Global Impression Efficacy Index (CGI-EI) will be filled. The investigator will perform MoCA testing. Safety laboratory tests (hematology, serum chemistry, urinalysis) will be carried out. Throughout the study the patient will receive the treatment approved by the decree of the RF Ministry of Health dated 29.12.2012 No. 740n "On approval of standard of special care in cerebral infarction" except for the products specified in section "Forbidden concomitant therapy".


Recruitment information / eligibility

Status Completed
Enrollment 246
Est. completion date February 7, 2023
Est. primary completion date February 7, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age between 40 and 75 years old inclusively. 2. Ischemic stroke in the carotid arteries (I 63) within 72 hours post debut. 3. Moderate cognitive disorders (MoCA < 26). 4. Normal consciousness (Glasgow score 15) 5. Stroke severity 8-12 according to NIHSS. 6. Disability mRs score 2-3. 7. Availability of cerebral CT/MRI within 72 hours post stroke debut. 8. Patients who agreed to use a reliable method of contraception during the study. 9. Patients who have signed the Participant Information Sheet and Informed Consent. Exclusion Criteria: 1. Current or previous subarachnoidal/parenchymatous/ventricular hemorrhage, cerebral infarction, cerebral tumour. 2. Cerebral CT/MRI findings suggesting cerebral hemorrhage, tumour within 72 hours post stroke debut. 3. Scheduled or completed thrombolytic therapy for the treatment of the current cerebral infarction. 4. Central nervous system (CNS) diseases including: - Inflammatory diseases of the central nervous system (G00-G09); - Systemic atrophies primarily affecting the central nervous system (G10-G13); - Extrapyramidal and movement disorders (G20-G26); - Other degenerative diseases of the nervous system (G30-G32); - Demyelinating diseases of the CNS (G35-G37); - Episodic and paroxysmal disorders (G40-G47); - Polyneuropathies and other disorders of the peripheral nervous system (G60-64), with marked movement and/or sensory impairments that cause movement disorders; - Hydrocephalus (G91). 5. (History of) injuries to the head (S00-S09) associated with impaired consciousness, cerebral contusion or open craniocerebral trauma. 6. Musculoskeletal disorders causing motor disturbances. 7. (History of) dementia (F00-F03). 8. Malignant neoplasms. 9. Patients previously diagnosed with class IV heart failure (1964 New York Heart Association functional classification), hypothyroidism, or poorly treated diabetes mellitus. 10. Patients having unstable angina or myocardial infarction in the past 6 months. 11. Allergy/ intolerance to any of the components of medications used in the treatment. 12. Malabsorption syndrome, including congenital or acquired lactase deficiency (or any other disaccharidase deficiency) and galactosemia. 13. Any conditions which, according to the investigator opinion, may interfere with the subject's participation in the study. 14. Prior history of non-adherence to a drug regimen, a psychiatric disorder, alcoholism or drug abuse, which, in the opinion of the investigator, can compromise compliance with study protocol. 15. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial. 16. Participation in other clinical studies within 3 month prior to enrollment in the study. 17. Patients who are related to any of the on-site research personnel directly involved in the conduct of the trial or are an immediate relative of the study investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted). 18. Patients who work for OOO "NPF "Materia Medica Holding" (i.e. the company's employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).

Study Design


Intervention

Drug:
MMH-MAP
Oral administration.
Placebo
Oral administration.

Locations

Country Name City State
Russian Federation Arkhangelsk Regional Clinical Hospital/Neurological Department Arkhangelsk
Russian Federation The First City Clinical Hospital named after E.E. Volosevich Arkhangelsk
Russian Federation Belgorod Regional Clinical Hospital of St. Joasaph Belgorod
Russian Federation Regional Clinical Hospital # 3 Chelyabinsk
Russian Federation City Clinical Hospital # 7 Kazan
Russian Federation Interregional Clinical Diagnostic Center Kazan
Russian Federation Kazan State Medical University/Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan Kazan
Russian Federation Research Institute - Regional Clinical Hospital # 1 named after Prof. S.V. Ochapovsky Krasnodar
Russian Federation Central Clinical Hospital of the Russian Academy of Sciences Moscow
Russian Federation City Clinical Hospital named after V.M. Buyanov, Moscow Department of Health Moscow
Russian Federation City Clinical Hospital # 5 of the Nizhegorodskiy District of Nizhny Novgorod Nizhny Novgorod
Russian Federation Novosibirsk State Regional Clinical Hospital Novosibirsk
Russian Federation Regional Clinic Hospital/Emergency cardiology unit with intensive care and resuscitation unit Ryazan
Russian Federation City Multidisciplinary Hospital # 2 Saint Petersburg
Russian Federation St. Petersburg Research Institute of Ambulance named after I.I. Janelidze Saint Petersburg
Russian Federation Samara City Clinical Hospital # 1 named after N.I. Pirogov/Neurological Department Samara
Russian Federation Saratov City Clinical Hospital # 9 Saratov
Russian Federation Ulyanovsk Regional Clinical Hospital/Neurological Department Ulyanovsk
Russian Federation Regional Clinic Hospital/Neurological department for patients with acute cerebrovascular accident Vladimir
Russian Federation Voronezh Regional Clinical Hospital # 1 Voronezh
Russian Federation Vsevolozhsk Clinical Interdistrict Hospital Vsevolozhsk
Russian Federation Clinical Hospital # 8/Intensive Care Unit Yaroslavl

Sponsors (1)

Lead Sponsor Collaborator
Materia Medica Holding

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average MoCA score. Montreal Cognitive Assessment Scale (The Montreal Cognitive Assessment, MoCA) will be used to identify moderate cognitive impairment, as well as to assess changes in cognitive functions during therapy. The time for MoCA is approximately 10 minutes. The maximum possible number of points is 30; 26 points or more is considered normal. On the 90th day of the treatment period.
Secondary Changes in NIHSS score. NIHSS Scale (National Institutes of Health Stroke Scale) is a scale for assessing the severity of neurological disorders of the acute period of ischemic stroke. The NIHSS scale involves the assessment of a neurological condition by generally accepted methods of clinical examination of reflexes, sensory organs, and the patient's level of consciousness. The results range from minimum indicators - normal or close to normal, to maximum - reflect the degree of neurological damage. On the days 12, 90 of the treatment period.
Secondary Percentage of patients with no significant disabilities. The modified Rankin scale (mRs 0-1) allows to assess the grade of disability after a stroke. The scale includes five grades of disability: from 0 to 5: 0 - no symptoms, 5 - gross disability; bedridden, fecal and urinary incontinence, need for constant assistance by medical staff. On the 90th day of the treatment period.
Secondary Therapeutic and side effects, efficacy index. According to Clinical Global Impression Efficacy Index (CGI-EI).CGI-EI is filled out by an investigator. It is necessary to indicate the level of efficacy of the therapy and the grade of safety of the therapy and circle the index values at the intersection of the selected lines. On the 90th day of the treatment period.
Secondary Occurrence and nature of adverse events (AEs). Based on medical records. Occurrence, nature, severity, causality and outcome of adverse events (AEs). For 90 days of the treatment period.
Secondary Percentage of patients with ?omplication of cerebral infarction. Based on medical records. The sequelae of cerebral infarction (severe infections - hospital-acquired pneumonia, uroinfection; deep venous thrombosis, PATE; epileptic episodes). For 90 days of the treatment period.
Secondary Death rate. Based on medical records. Frequency of all-cause mortality outcomes. For 90 days of the treatment period.
Secondary Changes in vital signs (pulse rate (heart rate)). Based on medical records. Vital signs will be measured in a medical setting. For 90 days of the treatment period.
Secondary Changes in vital signs (respiration rate (breathing rate)). Based on medical records. Vital signs will be measured in a medical setting. For 90 days of the treatment period.
Secondary Changes in vital signs (blood pressure). Based on medical records. Vital signs will be measured in a medical setting. For 90 days of the treatment period.
Secondary Percentage of patients with clinically significant abnormal laboratory data. Based on medical records. For 90 days of the treatment period.
Secondary Percentage of patients with recurring cerebral infarction. Based on medical records. For 90 days of the treatment period.
See also
  Status Clinical Trial Phase
Completed NCT02554253 - The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction Phase 2
Recruiting NCT02777060 - Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures N/A
Completed NCT02342041 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects Phase 1
Recruiting NCT01659593 - Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients N/A
Completed NCT01561820 - Mild Cognitive Impairment, Buddy Supported Exercise/ My Buddy Study N/A
Completed NCT00743405 - Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects Phase 1
Completed NCT05373394 - Evaluation of Cognitive and Motor Neurological Disorders in the Short and Long Term After Surgery for the Removal of a Diffuse Low-grade Glioma of the Supplementary Motor Area
Completed NCT04860414 - Prospective Monocentric Study of Taste in Patients With Minor or Major Cognitive Disorders Such as Alzheimer's, Through the Analysis of Gustatory Evoked Potentials. N/A
Completed NCT02324153 - Ramelteon in the Prevention of Post-operative Delirium Phase 2
Completed NCT00458094 - Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses N/A
Completed NCT05486195 - A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect Phase 1
Not yet recruiting NCT03866018 - Contribution of Physical Activity to Self-esteem and Motivation in Older Adults With Minor to Major Cognitive Disorders Such as Alzheimer's Disease or Related Disorders N/A
Recruiting NCT02876536 - Effect of Transcutaneous Electrical Nerve Stimulation on Cognition in Multiple Sclerosis Patients N/A
Completed NCT02321475 - EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
Completed NCT01881646 - Postoperative Neuroinflammation and Cognitive Dysfunction After Abdominal Surgery Phase 4
Recruiting NCT05888961 - Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials N/A
Completed NCT01983384 - Anesthetic Depth and Postoperative Delirium Trial - 2 N/A
Completed NCT02575482 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects Phase 1
Completed NCT00937846 - Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study Phase 1
Completed NCT01772095 - ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE N/A